Drug Trial Radar · NCT03078075
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
403
Actual
Start
May 5, 2017
Primary completion
Jul 3, 2019
Study completion Jul 25, 2019
Sponsor
- Lead sponsor
- University of Texas Southwestern Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA); The Emmes Company, LLC
- First posted
- Mar 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.
Conditions
- Methamphetamine Use Disorder
Interventions
Naltrexone: Vivitrol®Drug
Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks
Placebo (PLB) InjectableDrug
Placebo: 4 intramuscular injections administered every 3 weeks
Bupropion: Wellbutrin XL®Drug
Bupropion: 450 mg oral dose daily
Placebo (PLB) OralDrug
Placebo: once-daily oral placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Response During Medication Phase at Stage 1Time frame: At week 6
- Number of Participants in Placebo Arm With Treatment Response During Medication Phase at Stage 2Time frame: At week 12
- Number of Participants With Treatment Response During Medication Phase at Stage 1 (by Race)Time frame: At week 6
- Number of Participants With Treatment Response During Medication Phase at Stage 1 (by Ethnicity)Time frame: At Week 6
- Number of Participants With Treatment Response During Medication Phase at Stage 1 (by Sex)Time frame: At week 6
- Number of Participants With Treatment Response During Medication Phase at Stage 2 (by Race)Time frame: At week 12
- Number of Participants With Treatment Response During Medication Phase at Stage 2 (by Ethnicity)Time frame: at Week 12
- Number of Participants With Treatment Response During Medication Phase at Stage 2 (by Sex)Time frame: At week 12
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles (UCLA) Center for Behavioral Addiction Medicine (CBAM)
Los Angeles, California
Substance Use Research Unit (SURU) at the San Francisco Dept. of Public Health
San Francisco, California
Hennepin County Medical Center- Berman Center for Research
Minneapolis, Minnesota
New York State Psychiatric Institute (NYSPI)- Substance Use Research Center (SURC)
New York, New York
CODA, Inc.
Portland, Oregon
Behavioral Health Services (BHS) of Pickens County
Pickens, South Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
University of Texas Health Science Center - Center for Neurobehavioral Research on Addiction (CNRA)
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.